Botox for Migraine Billing: 64615 + J0585 Rules (2026)

If your neurology or headache clinic runs a regular Botox-for-migraine schedule, you already know the pattern: the clinical workflow is routine, the patients are scheduled out 12 weeks in advance, and yet a frustrating percentage of those clean clinical encounters come back denied. Wrong units on J0585. Prior auth expired. Procedure code mismatch. Documentation “insufficient.” Each denial is a $1,100–$1,200 hole in the schedule, and most are entirely preventable.

This is the fifth post in our neurology cluster, and we’re focusing on the single highest-dollar recurring procedure most neurology practices bill: chemodenervation with onabotulinumtoxinA for chronic migraine under the PREEMPT protocol. We’ll walk through the two-code structure, the 31 vs 39 injection-site rule, J0585 unit accounting, the prior auth gauntlet, Medicare quirks, and the top denial patterns we see across our neurology book of business. AMS Solutions has been billing for specialty practices since 1992, and our AAPC-certified coders process more than 3 million claims annually with a 95%+ clean claim rate — Botox-for-migraine is one of the procedures where that discipline pays off most visibly.

The two-code structure — procedure plus drug

A chronic migraine Botox encounter is always billed as two line items on the same claim: the procedure (CPT 64615) and the drug supply (HCPCS J0585). Get either one wrong and the entire encounter is at risk.

• CPT 64615 — Chemodenervation of muscles innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (e.g., for chronic migraine). This is the procedural code specifically created for the PREEMPT chronic migraine protocol. Reimbursement is roughly $140 in 2026 depending on locality. Do not confuse this with 64612, which is chemodenervation of muscles innervated by the facial nerve unilateral (e.g., blepharospasm, hemifacial spasm) — different indication, different payment, and a denial waiting to happen if a coder picks it from a dropdown by habit.
• HCPCS J0585 — Injection, onabotulinumtoxinA, 1 unit. The PREEMPT protocol calls for 155 units, so the line item should read “J0585 x 155.” At an ASP+6% rate of roughly $6.30 per unit in 2026, that’s about $975 in drug reimbursement.

Total expected per-encounter revenue, when billed correctly: approximately $1,100–$1,200. Multiply that across a panel of 40 chronic migraine patients on a 12-week cadence and you’re looking at a six-figure annual line item that lives or dies on documentation discipline.

The 31 vs 39 injection-site rule

The PREEMPT protocol specifies 31 fixed injection sites totaling 155 units across seven specific muscle groups (corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinal, trapezius). That’s the baseline.

The protocol also allows a “follow-the-pain” optional component — up to 8 additional sites in the temporalis, occipitalis, and trapezius regions, for a maximum of 39 total sites and 195 units. Many providers use this option for patients with localized pain patterns.

Here’s the audit trap: if the provider billed 195 units of J0585 but the procedure note only documents the 31 fixed sites, that’s a recoupment scenario on post-payment review. Documentation must specify the actual injection sites used — ideally as a numbered list or a labeled diagram in the chart — and the units delivered at each site must reconcile to the J0585 unit count on the claim. “155 units administered per PREEMPT” is not enough on its own; auditors want to see sites listed.

J0585 unit accounting — the most common denial driver

If we had to pick the single biggest source of preventable lost revenue on Botox claims, it’s J0585 unit math. The rule is straightforward but easy to miss in a busy clinic.

• Units billed equal units delivered to the patient, not units drawn from the vial.
• JW and JZ are national CMS requirements (since 7/1/2023), not MAC-specific. Bill JW on a separate line for the discarded amount from a single-use vial. Bill JZ on the primary line when there is no discarded amount. Missing either modifier results in CMS rejection — this isn’t optional.
• Botox onabotulinumtoxinA (J0585) is supplied in single-use vials per FDA labeling. Vial sharing across patients is not consistent with FDA labeling and creates both clinical and billing risk; most practices should plan on per-patient single-use vial accounting. If your protocol differs, confirm payer policy and document accordingly.
• Example: A 200-unit single-use vial used for a 155-unit patient — bill J0585 x 155 on the primary line and J0585 x 45 with JW modifier on a separate line. A 100-unit patient using a 100-unit vial with zero waste — bill J0585 x 100 with JZ modifier on the primary line.

The top recurring J0585 denial we see: units on the claim don’t match what the procedure note documents. This is a scrubber-rule problem, not a clinical problem — every claim with 64615 should be auto-paired with a J0585 unit count that matches the documented administration before it leaves the office.

Prior auth — the gauntlet

Almost every commercial payer requires prior authorization for chronic migraine Botox. Skipping this step or letting an auth lapse is one of the fastest ways to write off a $1,200 encounter. To get an auth approved (and renewed), expect to document:

• Diagnosis of chronic migraine with an ICD-10 code from the G43.7x family (typically G43.701 or G43.711).
• Failure of at least two preventive medications from different classes (e.g., a beta blocker, a tricyclic, an anticonvulsant, or a CGRP inhibitor), including the drug name, dose, duration of trial, and reason for discontinuation (ineffective, intolerable side effect, contraindicated).
• A headache diary or attestation showing ≥15 headache days per month, including ≥8 migraine days, sustained for at least three months.
• For reauth (typically every 6 months): documented response to prior treatment — usually a ≥50% reduction in headache days or meaningful disability score improvement.

One more trap: most commercial plans (and Medicare LCDs) require a minimum 12-week interval between treatments. Billing day 83 instead of day 84 will get you a hard denial that’s painful to appeal. Build the 12-week rule into your scheduling template, not just your billing scrubber.

Medicare specifics

Medicare covers chronic migraine Botox when medical necessity is documented, but coverage rules live in Local Coverage Determinations (LCDs) that vary by MAC. Before you bill your first Medicare Botox claim, pull your MAC’s LCD for chemodenervation and read it end-to-end. Key things to confirm:

• Whether your MAC requires modifier KX on the 64615 line to attest that medical necessity criteria have been met.
• The specific diagnosis codes your MAC will accept on the claim (some LCDs are stricter than others on G43.7x sub-codes).
• The MAC’s documented frequency limit (almost always 12 weeks minimum).
• Whether the MAC has a published list of acceptable prior preventive medications.

Medicare Advantage plans may add their own prior auth layer on top of the Medicare LCD. Treat MA as commercial for auth-tracking purposes.

Documentation requirements (what auditors actually check)

When a payer pulls a Botox encounter for review — pre-pay or post-pay — these are the five elements they’re looking for in the chart:

1. Diagnosis: chronic migraine with a specific G43.7x ICD-10 code.
2. Prior preventive medication failures: drug name, dose, duration, reason for discontinuation — for at least two agents from different classes.
3. Baseline headache burden: headache days per month and migraine days per month, ideally from a patient-completed diary.
4. Procedure detail: the actual injection sites used and units delivered per site, reconciling to total J0585 units billed.
5. Follow-up response: at the next visit, documented improvement (or lack thereof) — this is the basis for the reauth and the continuation decision.

A standardized chart template or dot phrase covering these five elements is the single highest-ROI change most clinics can make. It speeds the visit, satisfies the auditor, and feeds the prior auth packet without rework.

Top 5 64615 + J0585 denial patterns — and the fix for each

1. J0585 units don’t match documentation. Fix: a pre-submission scrubber rule that flags any 64615 claim where the J0585 unit count doesn’t reconcile to documented sites/units in the procedure note.
2. Prior auth expired or not on file. Fix: a 6-month auth tracker that surfaces upcoming expirations 30 days out, with the reauth packet (response data, updated diary) prepped automatically.
3. Billed before the 12-week minimum interval. Fix: schedule the next visit at the front desk at 84+ days, and build a hard rule in the scheduling system so a front-desk reschedule can’t pull the date in.
4. Missing failure-of-preventives documentation. Fix: a standardized prior-auth packet template that won’t submit without the required medication-history fields populated.
5. Wrong procedure code (64612 instead of 64615). Fix: a coder check on any chemodenervation claim — if the diagnosis is G43.7x, the procedure must be 64615, full stop.

Most of these fixes are workflow changes, not technology projects. The clinics that get this right treat the Botox program like a small assembly line: standardized template, standardized auth packet, standardized scrubber rules, standardized follow-up. Operationalizing this kind of process discipline is exactly where outsourced billing tends to outperform an in-house team juggling six specialties at once.

A real practice example

A 3-neurologist headache clinic in the Atlanta market came to us last year running a first-pass denial rate of roughly 35% on their Botox claims (the industry-acceptable target is under 10%). The clinical side was excellent — they were doing the injections correctly, their patients were responding — but the revenue side was bleeding. Most denials were the same handful of issues: J0585 unit mismatches, expired prior auths, and a recurring 64612-vs-64615 confusion from a coder who had come over from an ophthalmology practice.

Three interventions from our team:

• A prior auth tracker with 30-day expiration alerts and a pre-populated reauth packet.
• A pre-submission scrubber rule reconciling J0585 units to procedure-note documentation.
• A standardized dot phrase in the EHR covering the five auditor elements above.

Ninety days later, the first-pass denial rate was at 8% and the clinic had recovered approximately $45,000 in first-quarter revenue that would otherwise have been written off. No new clinicians, no new patients, no new contracts — just the operational discipline applied to a procedure they were already performing correctly.

Where this fits in the broader neurology revenue picture

Botox-for-migraine is one of the highest-leverage line items in a neurology P&L, but it sits inside a larger neurology revenue cycle that includes EEG, EMG/NCS, evaluation and management coding, and infusion therapy — each with its own documentation traps. We cover the full picture on our neurology medical billing pillar, and our Neurology CPT Cheat Sheet (2026) has the codes, modifiers, and documentation prompts your coders need on the wall.

AMS Solutions has been doing this for neurology practices since 1992. Our AAPC-certified coders handle more than 3 million claims annually, with a 95%+ clean claim rate, sub-6% denial rate, and 30–35 day A/R — the kind of numbers that turn a leaky Botox program into a reliable revenue line. Learn more about our medical billing services, or if you’d like to walk through your specific denial patterns with us, grab a 30-minute slot on the calendar and we’ll dig into your numbers together.